Výsledky vyhledávání - "Debra Freedholm"

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa

Autor: Dan Bloomfield, Naab M. Al‐Saady, Debra Freedholm, Sara Coulter, Norman E. Lepor, Xiaohui Wang, Nancy Widener, Mark Lovern, Constance Cullen, Byungdoo Alexander Yi, Emilie Simard

Publikováno v: Journal of Thrombosis and Haemostasis. 20:307-315

Background Factor XI (FXI) inhibition offers the promise of hemostasis-sparing anticoagulation for the prevention and treatment of thromboembolic events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec2022a6f5c2560d66f2ddc2a3e2cc7c
https://doi.org/10.1111/jth.15577

Zobrazit plný text záznamu

Development and Validation of a Specific and Sensitive Anti-Drug Antibody Assay for Abelacimab That Avoids False Positive Results Due to Factor XI Interference

Autor: Connie Cullen, Xiao-Yan Cai, Cansu Dernek, Debra Freedholm

Publikováno v: Blood. 138:4274-4274

Abelacimab is a fully human IgG1 monoclonal antibody that has dual activity against the inactive zymogen Factor XI (FXI) and the activated Factor XI (FXIa). Clinical trials for this investigational product are ongoing. As part of the initial assessme

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2fd247250fb6928fd4cc9da1aa4fbc4c
https://doi.org/10.1182/blood-2021-153363

Zobrazit plný text záznamu

Human Pharmacokinetics and Tolerability of L-365,260, a Novel Cholecystokinin-B Antagonist

Autor: M. Gail Murphy, Mary Swigar, James R. Seibold, Ji Zhang, Laura Clarke, Owen M. Wolkowitz, J. H. Lin, Kenneth Grasing, Debra Freedholm, Karen Putnam, Herbert Weingartner

Publikováno v: The Journal of Clinical Pharmacology. 36:292-300

A study was conducted to examine the tolerability and pharmacokinetics of single and multiple oral doses of L-365,260, a novel antagonist for type B cholecystokinin (CCK) receptors and to quantify effects of selective blockade of type B CCK receptors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd6e5b49356d2e0183ab054498d04e95
https://doi.org/10.1002/j.1552-4604.1996.tb04204.x

Zobrazit plný text záznamu

Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies

Autor: Marie-Pierre Malice, Pascale M. Chavassieux, A. John Yates, Debra Freedholm, Monique E. Arlot, Neveen A. T. Hamdy, Nathalie Portero, Pierre J. Meunier, Daifotis Anastasia G, Jean-Paul Roux

Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 15(4)

Effects of alendronate (ALN) on bone quality and turnover were assessed in 88 patients (52 women and 36 men aged 22-75 years) who received long-term oral glucocorticoid exposure. Patients were randomized to receive oral placebo or alendronate 2.5, 5,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f36ba2605dcf3a03116949674af8253e
https://pubmed.ncbi.nlm.nih.gov/10780867

Zobrazit plný text záznamu

The Assessment of Bone Mass in Men

Autor: Debra Freedholm, Philip D. Ross, Antonio Lombardi

Publisher Summary This chapter illustrates the clinical application of bone mineral density (BMD) measurements. Bone mineral density (BMD) is widely used to identify which female patients should be given therapy for prevention or treatment of osteopo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::753577c023bbae3b83c371a3fac9470b
https://doi.org/10.1016/b978-012528640-4/50025-3

Zobrazit plný text záznamu

Esophagitis associated with the use of alendronate

Autor: Haim Pinkas, Wendy P. Stephenson, Laurence J. Hirsch, Debra Freedholm, Suzanne Pryor-Tillotson, Piet C. de Groen, Dieter Lubbe, Kenneth K. Wang, Daifotis Anastasia G, Mitchel J. Seleznick

Publikováno v: The New England journal of medicine. 335(14)

Alendronate, an aminobisphosphonate and a selective inhibitor of osteoclast-mediated bone resorption, is used to treat osteoporosis in postmenopausal women and Paget's disease of bone. Aminobiphosphonates can irritate the upper gastrointestinal mucos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48a8413d5263a2ad3e14c125af6673b2
https://pubmed.ncbi.nlm.nih.gov/8801453

Zobrazit plný text záznamu

Upper Gastrointestinal Tract Safety Profile of Alendronate

Autor: Douglas C. Bauer, Desmond E. Thompson, Thomas Musliner, Michael C. Nevitt, Kristine E. Ensrud, Debra Freedholm, Marc C. Hochberg, Dennis Black

Publikováno v: Archives of Internal Medicine. 160:517

Objectives To determine whether alendronate sodium treatment is associated with upper gastrointestinal (GI) tract adverse experiences (AEs)—particularly those of the stomach, duodenum, or esophagus—in the Fracture Intervention Trial, and to asses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e17e7c29b2809e27d97407b17fb7124
https://doi.org/10.1001/archinte.160.4.517

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání